Genetically modified stem cells
Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
1. A population of isolated genetically engineered human beta cells comprising a nucleic acid encoding for exogenous or heterologous expression of a human CXCL12 protein isoform such that said population of said cells is characterized as encoding for the expression of a fugetactic amount of said CXCL12 protein isoform and is therefore resistant to cell death when in the presence of human immune cells in vitro as compared to a population of unengineered human beta cells obtained from a human stem cell that has been differentiated ex vivo into human beta cells,
wherein the nucleic acid is operably linked to an exogenous promoter,
wherein the population of genetically engineered human beta cells is insulin producing and has been exposed to a senescence inducing agent, and
wherein said population of genetically engineered human beta cells is obtained from a human stem cell that has been differentiated ex vivo into a human beta cell and is either autologous or allogeneic.
2. The population of isolated human beta cells of claim 1 , wherein the differentiated human beta cell is allogeneic.
3. The population of isolated human beta cells of claim 1 ,
wherein said fugetatic characterization is based on the relative amounts of lactate dehydrogenase (LDH) measured after assaying said population of engineered cells for 48 hours in the presence of human peripheral blood mononuclear cells (PBMCs) at a ratio of 1:30 genetically engineered beta cells to PBMCs; and
wherein the amount of LDH is decreased by at least 50% for said population of engineered human beta cells compared to that of a population of unengineered human beta cells and 95% of the engineered human beta cells survive after 48 hours of exposure to PBMCs.